178 related articles for article (PubMed ID: 12004345)
1. Is it cost-effective to treat recurrent hepatitis C infection in orthotopic liver transplantation patients?
Saab S; Ly D; Han SB; Lin RK; Rojter SE; Ghobrial RM; Busuttil RW
Liver Transpl; 2002 May; 8(5):449-57. PubMed ID: 12004345
[TBL] [Abstract][Full Text] [Related]
2. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
Saab S; Hunt DR; Stone MA; McClune A; Tong MJ
Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
[TBL] [Abstract][Full Text] [Related]
3. What is the cost-effectiveness of hepatitis C treatment for injecting drug users on methadone maintenance in New Zealand?
Sheerin IG; Green FT; Sellman JD
Drug Alcohol Rev; 2004 Sep; 23(3):261-72. PubMed ID: 15370005
[TBL] [Abstract][Full Text] [Related]
4. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
[TBL] [Abstract][Full Text] [Related]
5. Treatment of chronic hepatitis B with interferon-alpha: cost-effectiveness in developing countries.
Aggarwal R; Ghoshal UC; Naik SR
Natl Med J India; 2002; 15(6):320-7. PubMed ID: 12540064
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C virus sensitivity to combined antiviral therapy in liver transplant versus immunocompetent patients.
Redondo I; Otón E; Bárcena R; Del Campo S; Rodriguez-Gandía M; Cuervas-Mons V
Transplant Proc; 2009; 41(6):2195-6. PubMed ID: 19715871
[TBL] [Abstract][Full Text] [Related]
7. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis.
Rothberg MB; Rose DN
Am J Med; 2005 Jan; 118(1):68-77. PubMed ID: 15639212
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of antiviral treatment in liver transplant recipients with HCV infection.
Logge C; Vettorazzi E; Fischer L; Nashan B; Sterneck M
Transpl Int; 2013 May; 26(5):527-34. PubMed ID: 23517333
[TBL] [Abstract][Full Text] [Related]
9. Relapse response to interferon and ribavirin in liver transplant recipient with hepatitis C recurrence.
Coccoli P; Cordone G; Bruno M; Parrilli G
Transplant Proc; 2005 Dec; 37(10):4406-7. PubMed ID: 16387132
[TBL] [Abstract][Full Text] [Related]
10. Antiviral therapy for hepatitis C virus recurrence following liver transplantation: long-term results from a single center experience.
Burra P; Targhetta S; Pevere S; Boninsegna S; Guido M; Canova D; Brolese A; Masier A; D'Aloiso C; Germani G; Tomat S; Fagiuoli S
Transplant Proc; 2006 May; 38(4):1127-30. PubMed ID: 16757285
[TBL] [Abstract][Full Text] [Related]
11. Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12.
Raziorrouh B; Jung MC; Schirren CA; Loehe F; Thiel M; Nitschko H; Diepolder H; Ulsenheimer A; Heeg M; Zachoval R; Gruener NH
Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):778-83. PubMed ID: 18617783
[TBL] [Abstract][Full Text] [Related]
12. Treatment for recurrent hepatitis C.
Ghobrial RM
Minerva Chir; 2003 Oct; 58(5):693-703. PubMed ID: 14603148
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.
Manser R; Dalton A; Carter R; Byrnes G; Elwood M; Campbell DA
Lung Cancer; 2005 May; 48(2):171-85. PubMed ID: 15829317
[TBL] [Abstract][Full Text] [Related]
14. Humoral immune response to hepatitis C after liver transplantation: assessment of a new recombinant immunoblot assay.
Rosen HR; Gretch D; Kaufman E; Quan S
Am J Gastroenterol; 2000 Aug; 95(8):2035-9. PubMed ID: 10950054
[TBL] [Abstract][Full Text] [Related]
15. Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C.
Buti M; San Miguel R; Brosa M; Cabasés JM; Medina M; Angel Casado M; Fosbrook L; Esteban R
J Hepatol; 2005 May; 42(5):639-45. PubMed ID: 15826711
[TBL] [Abstract][Full Text] [Related]
16. [The course of hepatitis C infection after liver transplantation].
Ołdakowska-Jedynak U; Paczek L
Pol Merkur Lekarski; 2005 Aug; 19(110):220-4. PubMed ID: 16245439
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of screening for hepatopulmonary syndrome in liver transplant candidates.
Roberts DN; Arguedas MR; Fallon MB
Liver Transpl; 2007 Feb; 13(2):206-14. PubMed ID: 17205561
[TBL] [Abstract][Full Text] [Related]
18. Factors that identify survival after liver retransplantation for allograft failure caused by recurrent hepatitis C infection.
Neff GW; O'Brien CB; Nery J; Shire NJ; Nishida S; delaGarza J; Montalbano M; Safdar K; Ruiz P; Rideman E; Gascon JA; Tzakis AG; Madariaga J; Rudich SM
Liver Transpl; 2004 Dec; 10(12):1497-503. PubMed ID: 15558835
[TBL] [Abstract][Full Text] [Related]
19. Prophylaxis and treatment of recurrent viral hepatitis after liver transplantation.
Riediger C; Berberat PO; Sauer P; Gotthardt D; Weiss KH; Mehrabi A; Merle U; Stremmel W; Encke J
Nephrol Dial Transplant; 2007 Sep; 22 Suppl 8():viii37-viii46. PubMed ID: 17890261
[TBL] [Abstract][Full Text] [Related]
20. Management of hepatitis C virus infection in the setting of liver transplantation.
Rodriguez-Luna H; Vargas HE
Liver Transpl; 2005 May; 11(5):479-89. PubMed ID: 15838917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
